Ocuphire Pharma Investor Day Presentation Deck
RM
65
Reversal of Mydriasis (RM) Market Opportunity
With No Commercially Available Treatment, Nyxol may Achieve Significant Revenue Potential
Global Data Market Research Findings
101M
Annual
Dilations
95% of
Dilating
Drops Used
by ECPs
80% of
Patients
Likely to
Request
Drop
Source: GlobalData Market Research Survey
65% Report
Moderate to
Severe
Impact to
Daily
Function
Patient
Willingness
to Pay $10 to
$20+
$500+M
Estimated US RM Market
Opportunity
58%
physicians would start
prescribing Nyxol
within 1st year
81%
patients would be more
likely to schedule yearly
eye exams with a
reversal drop
0
Current Commercially
Available Treatments
68%
physicians would be
willing to use Nyxol
even if patients had to
still wear sunglasses
within 1st hour
Ocuphire
PHARMAView entire presentation